Skip to main content
. 2021 Jun 22;17(10):2606–2621. doi: 10.7150/ijbs.60292

Figure 6.

Figure 6

Knockdown of MEG3 promoted tumor growth and inhibited DDP chemotherapy sensitivity in vivo. A) Effect of MEG3 knockdown was confirmed by qRT-PCR. *P<0.05. B) Tumor sizes in BALB/C nude mice of three treatment groups. C) Representative images of tumors taken at the end of the study. D) Tumor growth curves of three treatment groups. Comparisons were made between the PBS negative control group and Lv-sh-NC + DDP treatment group (*P<0.05; **P<0.01), and between the Lv-sh-NC + DDP treatment group and Lv-sh-MEG3 + DDP treatment group (#P<0.05; ##P<0.01). Day 0 was defined as the day before PBS or DDP injection. E) Tumor weight of three treatment groups. The dose of DDP in the above-mentioned in vivo experiments was 5 mg/kg twice a week and continued to 24 days. *P<0.05; **P<0.01. Data are shown as mean ± SD (n=8). Lv-sh-MEG3, recombinant lentivirus expressing shRNA targeting MEG3; Lv-sh-NC, negative control of Lv-sh-MEG3.